-5.80%
-24.90%
-47.72%
-28.31%
-27.42%
-65.53%
-74.05%
AI Spotlight on IOVA
Company Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells.It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma.Iovance Biotherapeutics, Inc.
has collaborations and licensing agreements with H.Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG.The company was formerly known as Lion Biotechnologies, Inc.
and changed its name to Iovance Biotherapeutics, Inc.in June 2017.Iovance Biotherapeutics, Inc.
was incorporated in 2007 and is headquartered in San Carlos, California.
Market Data
| Last Price | 5.85 |
| Change Percentage | -5.80% |
| Open | 6.12 |
| Previous Close | 6.21 |
| Market Cap ( Millions) | 1783 |
| Volume | 8880221 |
| Year High | 18.33 |
| Year Low | 5.57 |
| M A 50 | 7.59 |
| M A 200 | 9.35 |
Financial Ratios
| FCF Yield | -20.98% |
| Dividend Yield | 0.00% |
| ROE | -58.43% |
| Debt / Equity | 10.21% |
| Net Debt / EBIDTA | 21.51% |
| Price To Book | 2.29 |
| Price Earnings Ratio | -4.33 |
| Price To FCF | -4.77 |
| Price To sales | 19.62 |
| EV / EBITDA | -4.28 |
News
- Jan -30 - What's Wrong With Iovance Biotherapeutics Stock?
- Jan -29 - Where Will Iovance Biotherapeutics Be in 5 Years?
- Jan -27 - Meet the Growth Stock That Could Soar 280%, According to Wall Street Analysts
- Jan -18 - 3 Stocks That Could Turn $1,000 Into $5,000 by 2030
- Jan -17 - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Jan -13 - Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
- Jan -09 - 3 Mid-Cap Stocks That Could Take Off in 2025
- Jan -03 - Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today
- Dec -20 - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Dec -19 - If I Could Only Buy 3 Stocks in the Last Month of 2024, I'd Pick These
- Dec -17 - 2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?
- Dec -12 - Prediction: This Stock Will Beat the Market in 2025
- Dec -07 - 3 Monster Stocks to Hold for the Next 10 Years
- Nov -27 - Is Iovance Biotherapeutics Stock a Millionaire Maker?
- Nov -26 - Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
- Nov -23 - Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back
- Nov -22 - 2 Innovative Stocks That Could Deliver Outsize Returns
- Nov -16 - 2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
- Nov -11 - Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity
- Nov -08 - IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Autologous Tumor Infiltrating Lymphocytes
Expected Growth : 11.53 %
What the company do ?
Autologous Tumor Infiltrating Lymphocytes (TIL) from Iovance Biotherapeutics, Inc. is a cancer treatment that uses a patient's own immune cells to fight cancer.
Why we expect these perspectives ?
Iovance Biotherapeutics' Autologous Tumor Infiltrating Lymphocytes' 11.53% growth is driven by increasing adoption in metastatic melanoma treatment, strong clinical trial results, and expanding research in solid tumors. Additionally, growing demand for personalized cancer therapies and strategic partnerships contribute to the segment's growth.
Iovance Biotherapeutics, Inc. Products
| Product Range | What is it ? |
|---|---|
| Tumor Infiltrating Lymphocytes (TIL) | TIL is a type of adoptive cell therapy that utilizes a patient's own immune cells to target and attack cancer cells. |
| LN-145 | LN-145 is an autologous adoptive cell therapy that utilizes TIL to target and attack cancer cells. |
| LN-144 | LN-144 is an autologous adoptive cell therapy that utilizes TIL to target and attack cancer cells. |
| IOV-COM-101 | IOV-COM-101 is a personalized neoantigen-directed T cell therapy that targets specific cancer mutations. |
Iovance Biotherapeutics, Inc.'s Porter Forces
Threat Of Substitutes
Iovance Biotherapeutics, Inc. has a unique product pipeline, and there are limited substitutes available in the market, reducing the threat of substitutes.
Bargaining Power Of Customers
Iovance Biotherapeutics, Inc. has a diverse customer base, and customers have some bargaining power due to the availability of alternative treatments, but the company's unique products and services mitigate this power.
Bargaining Power Of Suppliers
Iovance Biotherapeutics, Inc. has a diversified supplier base, and suppliers have limited bargaining power due to the company's strong negotiating position and the availability of alternative suppliers.
Threat Of New Entrants
The biotechnology industry is highly competitive, and new entrants can easily enter the market, posing a significant threat to Iovance Biotherapeutics, Inc.'s market share and revenue.
Intensity Of Rivalry
The biotechnology industry is highly competitive, and Iovance Biotherapeutics, Inc. faces intense rivalry from established companies and new entrants, leading to a high level of competition.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 1.48% |
| Debt Cost | 3.95% |
| Equity Weight | 98.52% |
| Equity Cost | 7.21% |
| WACC | 7.16% |
| Leverage | 1.50% |
Iovance Biotherapeutics, Inc. : Quality Control
Iovance Biotherapeutics, Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| DNLI | Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, … |
| IONS | Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for … |
| JANX | Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product … |
| FOLD | Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the … |
| RVMD | Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Denali Therapeutics
A-Score
1-Year Total Return ->
🥈
Revolution Medicines
A-Score
1-Year Total Return ->
🥉
Janux Therapeutics
A-Score
1-Year Total Return ->
4
Amicus Therapeutics
A-Score
1-Year Total Return ->
5
Ionis Pharmaceuticals
A-Score
1-Year Total Return ->
6
